{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:49:54Z","timestamp":1790250594330,"version":"4.1.0"},"reference-count":93,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2019,3,15]],"date-time":"2019-03-15T00:00:00Z","timestamp":1552608000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Current treatment of chronic hepatitis D viral infection with interferons is poorly tolerated and effective only in a minority of patients. Despite delta virus causing the most severe form of chronic viral hepatitis, no other treatments are available. After many years of inactivity, there is now hope for new treatment approaches for delta virus and some are likely to enter clinical practice in the near future. Four new treatment approaches are currently being evaluated in phase 2 studies. These involve the hepatocyte entry inhibitor myrcludex B, the farnesyl transferase inhibitor lonafarnib, the nucleic acid inhibitor REP 2139 Ca and pegylated interferon lambda. Results obtained so far are promising, and phase 3 studies are expected shortly. This review summarizes the available data on the efficacy and safety of these new drugs.<\/jats:p>","DOI":"10.1111\/jvh.13081","type":"journal-article","created":{"date-parts":[[2019,2,16]],"date-time":"2019-02-16T16:43:48Z","timestamp":1550335428000},"page":"618-626","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["New treatment options for delta virus: Is a cure in sight?"],"prefix":"10.1111","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5419-7158","authenticated-orcid":false,"given":"Cihan","family":"Yurdaydin","sequence":"first","affiliation":[{"name":"Department of Gastroenterology Ankara University Medical School  Ankara Turkey"},{"name":"Department of Gastroenterology and Hepatology Koc University  Istanbul Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,3,15]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.18.12.997"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.77.10.6124"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(82)90156-8"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(84)80153-5"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2010.01324.x"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.1840080631"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(87)80032-6"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/155.5.931"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(88)80457-4"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.46.3.420"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.07.005"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a021543"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.11796.1"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70563-9"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2010.01353.x"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu167"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.10.007"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1323629"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0912696"},{"key":"e_1_2_5_21_1","article-title":"Treatment of hepatitis delta with peginterferon plus tenofovir or placebo for 96\u00a0weeks: the HIDIT\u20102 study","author":"Wedemeyer H","year":"2018","journal-title":"Lancet Infect Dis."},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27102"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.1996.tb00002.x"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/135965350501000603"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2007.00875.x"},{"key":"e_1_2_5_26_1","first-page":"1648","article-title":"Pegylated interferon alfa\u20102B for chronic delta hepatitis: 12 versus 24\u00a0months","volume":"58","author":"\u00d6rmeci N","year":"2011","journal-title":"Hepatogastroenterology"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2016.1175310"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70409-9"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22654"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0022415"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27357"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix656"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2015.05.029"},{"key":"e_1_2_5_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2007.00936.x"},{"key":"e_1_2_5_35_1","first-page":"974A","article-title":"Early on\u2010treatment HDV RNA kinetics are not predictive for longterm response to a Peg\u2010IFN therapy of hepatitis delta (abstract)","volume":"60","author":"W\u00f6bse M","year":"2014","journal-title":"Hepatology"},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28876"},{"key":"e_1_2_5_37_1","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1177\/135965350801300110","article-title":"Does treatment of hepatitis B virus infection reduce hepatitis delta virus replication in HIV\u2010HBV\u2010HDV\u2010coinfected patients?","volume":"13","author":"Sheldon J","year":"2008","journal-title":"Antiviral Ther"},{"key":"e_1_2_5_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510300217"},{"key":"e_1_2_5_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02542.x"},{"key":"e_1_2_5_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(02)00162-9"},{"key":"e_1_2_5_41_1","unstructured":"YakutM SevenG BaranB et\u00a0al.Clevudine treatment of chronic delta hepatitis. In: EASL Monothematic Conference on Delta Hepatitis Abstract Book 2010; pp. 154 Istanbul Turkey"},{"key":"e_1_2_5_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cis459"},{"key":"e_1_2_5_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21282"},{"key":"e_1_2_5_44_1","doi-asserted-by":"publisher","DOI":"10.1177\/135965350701200307"},{"key":"e_1_2_5_45_1","doi-asserted-by":"publisher","DOI":"10.1089\/vim.2012.0036"},{"key":"e_1_2_5_46_1","first-page":"1549","article-title":"Hepatitis delta is a major determinant of liver decompensation events and death in HIV\u2010infected patients","volume":"58","author":"Soriano V","year":"2014","journal-title":"AIDS"},{"key":"e_1_2_5_47_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2013.0008"},{"key":"e_1_2_5_48_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix125"},{"key":"e_1_2_5_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21296"},{"key":"e_1_2_5_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2006.04082.x"},{"key":"e_1_2_5_51_1","article-title":"Treating chronic hepatitis delta: the need for surrogate markers of treatment efficacy","author":"Yurdaydin C","journal-title":"J Hepatol"},{"key":"e_1_2_5_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.05.043"},{"key":"e_1_2_5_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.13090"},{"key":"e_1_2_5_54_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2016.126"},{"key":"e_1_2_5_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21896"},{"key":"e_1_2_5_56_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26125"},{"issue":"1","key":"e_1_2_5_57_1","doi-asserted-by":"crossref","first-page":"e00049","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"13","author":"Yan H","year":"2012","journal-title":"Elife"},{"key":"e_1_2_5_58_1","doi-asserted-by":"publisher","DOI":"10.1006\/viro.1995.0002"},{"key":"e_1_2_5_59_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00096-07"},{"key":"e_1_2_5_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.04.013"},{"key":"e_1_2_5_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.04.016"},{"key":"e_1_2_5_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(18)30224-1"},{"key":"e_1_2_5_63_1","first-page":"11A","article-title":"Interim results of a multicentre, open\u2010label phase 2 clinical trial (MYR203) to assess safety and efficacy of Myrcludex B in combination with peg\u2010Interferon alpha 2a in patients with chronic HBV\/HDV co\u2010infection (abtsr.)","volume":"68","author":"Wedemeyer H","year":"2018","journal-title":"Hepatology."},{"key":"e_1_2_5_64_1","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000321"},{"key":"e_1_2_5_65_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1598578"},{"key":"e_1_2_5_66_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.20.10465-10472.2002"},{"key":"e_1_2_5_67_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI17704"},{"key":"e_1_2_5_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(15)00074-2"},{"key":"e_1_2_5_69_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29658"},{"key":"e_1_2_5_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(17)30310-0"},{"key":"e_1_2_5_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(17)30464-6"},{"key":"e_1_2_5_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(18)30397-0"},{"key":"e_1_2_5_73_1","first-page":"151A","article-title":"Prenylation inhibition of the large hepatitis delta virus antigen leads to intracellular accumulation of viral RNA and enhanced innate immune responses (abstr.)","volume":"66","author":"Lempp F","year":"2018","journal-title":"Hepatology."},{"key":"e_1_2_5_74_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.8b00156"},{"key":"e_1_2_5_75_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01003-13"},{"key":"e_1_2_5_76_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01005-13"},{"key":"e_1_2_5_77_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0156667"},{"key":"e_1_2_5_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(17)30288-1"},{"key":"e_1_2_5_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(18)31266-2"},{"key":"e_1_2_5_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2011.07.007"},{"key":"e_1_2_5_81_1","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02438-06"},{"key":"e_1_2_5_82_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21312"},{"key":"e_1_2_5_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2014.07.022"},{"key":"e_1_2_5_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.12.018"},{"key":"e_1_2_5_85_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-03946-9"},{"key":"e_1_2_5_86_1","first-page":"496A","article-title":"A phase 2 randomized clinical trial to evaluate the safety and efficacy of pegylated interferon lambda monotherapy in patients with chronic hepatitis delta virus infection. Interim results from the LIMT HDV study (abstr.)","volume":"66","author":"Hamid SS","year":"2017","journal-title":"Hepatology."},{"key":"e_1_2_5_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2017.05.002"},{"key":"e_1_2_5_88_1","first-page":"46A","article-title":"Final results of a phase 1b 28\u2010day study of ABI\u2010H0731, a novel core inhibitor, in non\u2010cirrhotic viremic subjects with chronic hepatitis B (abstr.)","volume":"68","author":"Yuen MF","year":"2018","journal-title":"Hepatology."},{"key":"e_1_2_5_89_1","first-page":"47A","article-title":"Safety, pharmacokinetics and antiviral activity of a novel hepatitis B virus capsid assembly modulator, JNJ\u2010561379, in patients with chronic hepatitis B (abstr.)","volume":"68","author":"Zoulim F","year":"2018","journal-title":"Hepatology."},{"key":"e_1_2_5_90_1","first-page":"LB25","article-title":"First results with RNA interference (RNAi) in chronic hepatitis B using ARO\u2010HBV (abstr.)","volume":"68","author":"Gane EJ","year":"2018","journal-title":"Hepatology."},{"key":"e_1_2_5_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.02.037"},{"key":"e_1_2_5_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.10.027"},{"key":"e_1_2_5_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(17)30315-X"},{"key":"e_1_2_5_94_1","first-page":"48A","article-title":"Iragivir demonstrates potent dose dependent anti\u2010viral activity in HBV\u2010treatment na\u00efve patients: role of HBeAg status and baseline HBsAg in anti\u2010viral response (abstr.)","volume":"68","author":"Yuen MF","year":"2018","journal-title":"Hepatology."}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjvh.13081","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.13081","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jvh.13081","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jvh.13081","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T22:06:29Z","timestamp":1694124389000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jvh.13081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,15]]},"references-count":93,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["10.1111\/jvh.13081"],"URL":"https:\/\/doi.org\/10.1111\/jvh.13081","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,15]]},"assertion":[{"value":"2018-11-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}